二肽基肽酶抑制剂联合二甲双胍对2型糖尿病合并代谢综合征患者血糖控制及HOMA-IR的影响

目的分析二肽基肽酶抑制剂联合二甲双胍对2型糖尿病合并代谢综合征患者血糖控制及胰岛素抵抗指数(HOMA-IR)的影响。方法选取某院2017年2月~2019年5月2型糖尿病合并代谢综合征患者76例,依照随机数字表法分组,各38例,对照组接受二甲双胍治疗,观察组接受二肽基肽酶抑制剂联合二甲双胍治疗,比较两组治疗前后血糖水平(空腹血糖、餐后2 h血糖)、血清炎性因子水平白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、HOMA-IR。结果与对照组对比,观察组治疗后空腹血糖、餐后2 h血糖较低(P<0.05);治疗后,观察组血清IL-1、TNF-α、hs-CRP较对照组低(P<0.05);治疗后,与对照组对比,观察组HOMA-IR较低(P<0.05)。结论二肽基肽酶抑制剂联合二甲双胍治疗2型糖尿病合并代谢综合征,能有效降低患者血糖水平,减少胰岛素抵抗,降低炎性因子水平。

Effects of dipeptidyl peptidase inhibitors and metformin on blood glucose control and HOMA-IR in patients with type 2 diabetes and metabolic syndrome

Objective To analyze the effects of dipeptidyl peptidase inhibitors and metformin on blood glucose control and insulin resistance index(HOMA-IR)in patients with type 2 diabetes and metabolic syndrome.Methods From February 2017 to May 2019,76 patients with type 2 diabetes and metabolic syndrome were selected from our hospital and grouped according to the random number table method,with 38 cases in each group.The control group received metformin treatment,and the observation group received dipeptidyl peptidase inhibitor combined with metformin treatment.Compare blood glucose levels(fasting blood glucose,2h postprandial blood glucose),serum inflammatory factor levelsinterleukin-1(IL-1),tumor necrosis factor-α(TNF-α),and hypersensitive C response protein(hs-CRP)],HOMA-IR before and after treatment between the two groups.Results Compared with the control group,the fasting blood glucose and 2 h postprandial blood glucose in the observation group were lower(P<0.05);After treatment,serum IL-1,TNF-α,and hs-CRP in the observation group were lower than those in the control group(P<0.05).After treatment,compared with the control group,HOMA-IR in the observation group was lower(P<0.05).Conclusion Dipeptidyl peptidase inhibitor combined with metformin in the treatment of type 2 diabetes with metabolic syndrome can effectively reduce blood glucose levels,reduce insulin resistance,and reduce inflammatory factor levels.